In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The project will leverage Noetik's AI model and multimodal spatial data to search for biomarkers of patient response to Agenus' immunotherapy regimen.

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

The firm is developing the PHOX2B-targeted cell therapy, which has shown promise in preclinical xenograft models, with CHOP researchers.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...